Deal Library / Pharma BD Deal Intelligence

Pharma Deals of 2024

The Pharma Closeout tracks 126 deals, $141.4B in disclosed deal value, 39 with a post-close Outcome Score for the year 2024.

Median Critic Score: 86  ·  Median Outcome Score: 65

Best outcome: Nuvation Bio Inc. / AnHeart Therapeutics, Ltd. (100)  ·  Weakest outcome: Ono Pharmaceutical / Shattuck Labs (28)

All 126 deals

• Nuvation Bio Inc. / AnHeart Therapeutics, Ltd. — 2024 · Worked — the deal delivered on its rationale.
• Novo Holdings A/S / Catalent (manufacturing sites) — 2024 · $11.0B · Worked — the deal delivered on its rationale.
• Novartis AG / PTC Therapeutics Inc. — 2024 · $2.9B · Worked — the deal delivered on its rationale.
• Vertex Pharmaceuticals Incorporated / Alpine Immune Sciences — 2024 · $4.9B · Worked — the deal delivered on its rationale.
• Johnson & Johnson / Shockwave Medical — 2024 · $13.1B · Worked — the deal delivered on its rationale.
• Gilead Sciences Inc. / CymaBay Therapeutics — 2024 · $4.4B · Worked — the deal delivered on its rationale.
• AstraZeneca PLC / Amolyt Pharma — 2024 · $1.1B · Largely worked — most objectives met.
• Sarepta Therapeutics Inc. / Arrowhead Pharmaceuticals Inc. — 2024 · $1.1B · Largely worked — most objectives met.
• Novartis AG / PeptiDream Inc. — 2024 · $2.9B · Largely worked — most objectives met.
• H. Lundbeck A/S / Longboard Pharmaceuticals, Inc. — 2024 · $2.6B · Largely worked — most objectives met.
• Novartis AG / Shanghai Argo Biopharmaceutical Co. Ltd. — 2024 · $4.2B · Largely worked — most objectives met.
• Sanofi SA / Inhibrx Inc. — 2024 · $2.2B · Largely worked — most objectives met.
• Harmony Biosciences / Epygenix Therapeutics — 2024 · $680M · Largely worked — most objectives met.
• Ono Pharmaceutical Co., Ltd. / Deciphera Pharmaceuticals — 2024 · $2.4B · Largely worked — most objectives met.
• Biogen Inc. / Human Immunology Biosciences — 2024 · $1.1B · Largely worked — most objectives met.
• Novartis / Arvinas, Inc. — 2024 · $1.2B · Largely worked — most objectives met.
• Bristol-Myers Squibb Company / Prime Medicine Inc. — 2024 · $3.5B · Largely worked — most objectives met.
• Gilead Sciences, Inc. / Xilio Therapeutics, Inc. — 2024 · $544M · Largely worked — most objectives met.
• Johnson & Johnson / Proteologix Inc. — 2024 · $850M · Largely worked — most objectives met.
• Merck & Co. Inc. / Harpoon Therapeutics — 2024 · $680M · Largely worked — most objectives met.
• Bristol-Myers Squibb Company / BioArctic AB — 2024 · $1.4B · Largely worked — most objectives met.
• Merck Sharp & Dohme LLC / Harpoon Therapeutics, Inc. — 2024 · $680M · Largely worked — most objectives met.
• AstraZeneca PLC / Fusion Pharmaceuticals Inc. — 2024 · $2.4B · Largely worked — most objectives met.
• Genmab A/S / ProfoundBio Inc. — 2024 · $1.8B · Largely worked — most objectives met.
• AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. — 2024 · $2.0B · Largely worked — most objectives met.
• Eli Lilly and Company / Morphic Holdings — 2024 · $3.2B · Largely worked — most objectives met.
• GSK plc / Duality Biologics (Suzhou) Co. Ltd. — 2024 · $975M · Largely worked — most objectives met.
• Merck & Co. Inc. / EyeBio Ltd. — 2024 · $3.0B · Largely worked — most objectives met.
• AbbVie Inc. / MedinCell S.A. — 2024 · $1.9B · Largely worked — most objectives met.
• Roche Holding AG / Poseida Therapeutics — 2024 · $1.5B · Largely worked — most objectives met.
• Novartis AG / Voyager Therapeutics Inc. — 2024 · $1.3B · Largely worked — most objectives met.
• GSK plc / Aiolos Bio — 2024 · $1.0B · Largely worked — most objectives met.
• AbbVie Inc. / EvolveImmune Therapeutics Inc. — 2024 · $1.5B · Mixed — partial payoff, real shortfalls.
• Johnson & Johnson / Ambrx Biopharma Inc. — 2024 · $2.0B · Mixed — partial payoff, real shortfalls.
• AbbVie Inc. / Aliada Therapeutics — 2024 · $1.4B · Mixed — partial payoff, real shortfalls.
• Sanofi SA / Novavax Inc. — 2024 · $1.2B · Mixed — partial payoff, real shortfalls.
• Merck & Co. Inc. / Modifi Biosciences — 2024 · $1.3B · Mixed — partial payoff, real shortfalls.
• Novartis AG / MorphoSys AG — 2024 · $2.9B · Underwhelmed — fell short of the thesis.
• Ono Pharmaceutical / Shattuck Labs — 2024 · $227M · Did not work — the deal failed to deliver.
• Bespin Subsidiary, LLC / Landos Biopharma Inc. — 2024
• Servier / Aitia — 2024
• Akari Therapeutics Plc / Peak Bio, Inc. — 2024
• Acino International AG / Allecra Therapeutics — 2024
• Merck & Co. Inc. / LaNova Medicines Ltd. — 2024 · $3.3B
• Bristol-Myers Squibb Company / Repertoire Immune Medicines Inc. — 2024 · $1.9B
• Ipsen / Sutro Biopharma — 2024 · $900M
• Sanofi SA / Belharra Therapeutics, Inc. — 2024 · $700M
• Roche Holding AG / Ascidian Therapeutics, Inc. — 2024 · $1.8B
• TuHURA Biosciences, Inc. / Kineta, Inc. — 2024
• AbbVie / OSE Immunotherapeutics — 2024
• Tenacia Biotechnology / Praxis Precision Medicines — 2024
• Reneo Pharmaceuticals, Inc. / OnKure, Inc. — 2024
• Astellas Pharma Inc. / Kelonia Therapeutics — 2024
• Organon & Co. / Dermavant Sciences Ltd. — 2024 · $1.2B
• Avalo Therapeutics, Inc. / AlmataBio, Inc. — 2024
• Proliant Health and Biologicals / Dyadic International, Inc. — 2024
• AbbVie / Nimble Therapeutics — 2024 · $200M
• Pieris Pharmaceuticals, Inc. / Palvella Therapeutics, Inc. — 2024
• Novo Nordisk A/S / Neomorph Inc. — 2024 · $1.5B
• Astellas / Sangamo Therapeutics — 2024
• Eli Lilly and Company / Radionetics Oncology Inc. — 2024 · $1.1B
• Ligand Pharmaceuticals Incorporated / APEIRON Biologics AG — 2024 · $100M
• Novartis AG / Mariana Oncology Inc. — 2024 · $1.8B
• ANI Pharmaceuticals, Inc. / Alimera Sciences, Inc. — 2024 · $381M
• Pfizer Inc. / Triana Biomedicines Inc. — 2024 · $1.5B
• Singapore Institute of Advanced Medicine Holdings / EnGeneIC Limited — 2024
• Hercules CM NewCo Inc. (Kailera Therapeutics) / Jiangsu Hengrui Pharmaceuticals Co. Ltd. — 2024 · $6.0B
• AstraZeneca PLC / CSPC Pharmaceutical Group Ltd. — 2024 · $2.0B
• AVROBIO, Inc. / Tectonic Therapeutic, Inc. — 2024
• Cara Therapeutics, Inc. / Tvardi Therapeutics, Inc. — 2024
• ReShape Lifesciences Inc. / Vyome Therapeutics, Inc. — 2024
• Eterna Therapeutics Inc. / Factor Bioscience Limited — 2024
• Insud Pharma / Agile Therapeutics, Inc. — 2024 · $45M
• Johnson & Johnson / Numab Therapeutics AG (Yellow Jersey Therapeutics) — 2024 · $1.2B
• Takeda Pharmaceutical Company Ltd. / Degron Therapeutics Ltd. — 2024 · $1.2B
• Merck & Co. Inc. / Curon Biopharmaceutical (Shanghai) Co. Ltd. — 2024 · $1.3B
• Intas Pharmaceuticals Ltd. / Coherus BioSciences, Inc. — 2024 · $558M
• Virtual Therapeutics Corporation / Akili, Inc. — 2024
• First Wave BioPharma, Inc. / ImmunogenX, Inc. — 2024
• Genentech, Inc. (Roche Group) / Regor Pharmaceuticals Inc. — 2024 · $850M
• CoreRx, Inc. / Societal CDMO — 2024
• Double Point Ventures LLC / Lumos Pharma, Inc. — 2024 · $38M
• Rani Therapeutics Holdings, Inc. / ProGen Co., Ltd. — 2024
• electroCore, Inc. / NeuroMetrix, Inc. — 2024
• Takeda Pharmaceutical Company Ltd. / AC Immune SA — 2024 · $2.2B
• AbbVie Inc. / Celsius Therapeutics Inc. — 2024 · $250M
• STADA Arzneimittel AG / Alvotech — 2024
• BioNTech SE / Biotheus Inc. (Pumai Biotechnology) — 2024 · $950M
• GSK plc / CureVac N.V. — 2024 · $1.6B
• Ipsen / Day One — 2024
• XOMA Corporation / Kinnate Biopharma Inc. — 2024
• Avextra AG / SynQube GmbH — 2024
• Neuronetics, Inc. / Greenbrook TMS — 2024
• Ensho Therapeutics, Inc. / EA Pharma Co., Ltd. — 2024
• Lyell Immunopharma, Inc. / ImmPACT Bio USA Inc. — 2024
• Ipsen S.A. / Marengo Therapeutics, Inc. — 2024 · $1.2B
• Immutep Limited / Cardiff University — 2024
• Space Finco, Inc. / Avid Bioservices, Inc. — 2024 · $1.1B
• Lantheus Holdings, Inc. / Life Molecular Imaging Ltd. — 2024
• I-MED Pharma Inc. / Kane Biotech Inc. — 2024
• Octane Medical Group / B. Braun Melsungen AG — 2024
• Roche / Medilink Therapeutics — 2024
• Novo Nordisk A/S / Biosplice Therapeutics, Inc. — 2024
• Eisai Co., Ltd. / SEED Therapeutics Inc. — 2024 · $1.5B
• Amneal Pharmaceuticals Inc. / Kashiv BioSciences LLC — 2024
• Glioblastoma Foundation, Inc. / Basilea Pharmaceutica Ltd — 2024
• NLS Pharmaceutics Ltd. / Kadimastem Ltd. — 2024
• Immunome Inc. / Ayala Pharmaceuticals, Inc. — 2024
• Eli Lilly and Company / HAYA Therapeutics SA — 2024 · $1.0B
• BiomX Inc. / Adaptive Phage Therapeutics, Inc. — 2024
• Monopar Therapeutics Inc. / NorthStar Medical Radioisotopes, LLC — 2024
• Chugai Pharma Europe Ltd. / Helsinn Group — 2024
• Otsuka Pharmaceutical Co., Ltd. / Jnana Therapeutics Inc. — 2024 · $1.1B
• Recordati S.p.A. / Sanofi SA — 2024 · $1.1B
• Incyte Corporation / Escient Pharmaceuticals Inc. — 2024 · $750M
• Relay Therapeutics / Pfizer Inc. — 2024
• Nika Pharmaceuticals, Inc. / Nika BioTechnology, Inc. — 2024
• Bayer AG / Dewpoint Therapeutics Inc. — 2024 · $424M
• Pharmacosmos A/S / G1 Therapeutics, Inc. — 2024
• AbbVie Inc. / Landos Biopharma Inc. — 2024 · $212M
• Avenzo Therapeutics Inc. / VelaVigo Bio Inc. — 2024 · $800M
• Kyowa Kirin Co. Ltd. / Kura Oncology Inc. — 2024 · $1.5B
• AbbVie Inc. / FutureGen Biopharmaceutical (Shanghai) Co. Ltd. — 2024 · $1.7B
• Takeda / Keros Therapeutics — 2024
• Biogen Inc. / Neomorph Inc. — 2024 · $1.4B
• Italfarmaco S.p.A. / Iktos — 2024

← Deal Library  ·  Interactive search  ·  How we score deals